Generation Bio (GBIO)
(Delayed Data from NSDQ)
$2.78 USD
-0.08 (-2.80%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $2.81 +0.03 (1.08%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
Brokerage Reports
0 items in cart
Generation Bio Co. [GBIO]
Reports for Purchase
Showing records 1 - 20 ( 48 total )
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
HEALTHCARE- ASGCT 2024 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Out with the Old (ce), In with the New (iq)DNA
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Potential Generational Shift in Genetic Medicines
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Moderna Deal Helps Get Closer to Proof of Concept
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Company: Generation Bio Co.
Industry: Medical - Generic Drugs
Heading Into a New Generation with Two Novel ctLNPs
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D